drug discovery Archives
A speedier treatment for depression?
Jul. 11, 2022—Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.
Looking beyond the ‘magic bullet’ approach to drug discovery
May. 1, 2018—Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.
Nashville Biosciences created to leverage wealth of data
Apr. 5, 2018—Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs
Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Vanderbilt, Ono Pharmaceutical extend drug discovery agreement
May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
Fighting fungal infections
Apr. 3, 2017—A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments.
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
VU takes key role in cancer drug discovery consortium
Jun. 23, 2016—Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.
